Topical cidofovir for severe warts in a patient affected by AIDS and Hodgkin's lymphoma

Abstract

We describe a 42-year-old man with AIDS and Hodgkin's lymphoma whose severe and recalcitrant cutaneous warts resolved following treatment with local 1% cidofovir. Clinically significant improvements were observed in a two-week period of therapy. In advanced HIV disease complicated by additional haematological malignancy, cutaneous warts may be difficult to treat and present a challenge for the attending physicians. In similar clinical condition topical anti-human papillomavirus therapy may prove to be safe and curative.

Treatment of Warts in Children With Focus on Recalcitrant Warts: A Narrative Review

“…Topical cidofovir has been successfully used with negligible risk in children with refractory warts (27). A case report demonstrated that this agent is effective in treating recalcitrant warts in immunocompromised patients (28).…”

Generalized verrucosis: A review of the associated diseases, evaluation, and treatments

“…128 Topical and intralesional cidofovir has been shown to be successful in the clearance of both genital and cutaneous verrucae, even in patients with AIDS and recurrent, diffuse verrucae. 143,144 Intravenous cidofovir was used in the case of an 11-year-old child with widespread, recalcitrant verrucae. Five cycles of intravenous cidofovir resulted in the clearance of her cutaneous disease, without recurrence.…”

Topical Cidofovir for Recalcitrant Verrucae in Individuals with Severe Combined Immunodeficiency After Hematopoietic Stem Cell Transplantation

“…Topical cidofovir has been successfully used with minimal risk in children with refractory warts (3). There are reports of safe and efficacious use of cidofovir in solid organ transplant recipients (4), and cidofovir has been shown in case reports to play a role in treating recalcitrant warts in immunocompromised patients, for example, in HIV (5). This is a case report of two brothers with X-SCID who had recalcitrant warts that cleared with topical cidofovir.…”